Cannabis Bioscience International Holdings (CBIH) Research & Development (2022 - 2026)

Cannabis Bioscience International Holdings has disclosed Research & Development across 5 years of filings, most recently posting $983.0 for Q1 2026.

• Research & Development for Q1 2026 came in at $983.0, up 357.21% year-over-year; the trailing twelve-month figure through Feb 2026 was $1321.0 (up 106.41% YoY), and the FY2025 annual result was $517.0, down 74.96% from the prior year.
• Research & Development came in at $983.0 for Q1 2026 at Cannabis Bioscience International Holdings, up from $62.0 in the prior quarter.
• In the past five years, Research & Development ranged from a high of $1772.0 in Q1 2023 to a low of $62.0 in Q4 2025.
• The 5-year median for Research & Development is $214.0 (2025), against an average of $661.64.
• Across the five-year window, Research & Development plunged 91.65% in 2024 and soared 357.21% in 2026, its largest moves.
• Cannabis Bioscience International Holdings' Research & Development stood at $1548.0 in 2022, then slumped by 87.27% to $197.0 in 2023, then slumped by 50.76% to $97.0 in 2024, then tumbled by 36.08% to $62.0 in 2025, then soared by 1485.48% to $983.0 in 2026.
• The last three Research & Development figures came in at $983.0 (Q1 2026), $62.0 (Q4 2025), and $213.0 (Q3 2025), per Business Quant data.